2-溴-5-(1,1-二甲基庚基)苯酚 | 70120-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-5-(1,1-二甲基庚基)苯酚
• 英文名称: 2-Brom-5-(1,1-dimethylheptyl)-phenol
• 英文别名: 2-(4-bromo-3-hydroxyphenyl)-2-methyloctane；2-Bromo-5-(2-methyloctan-2-YL)phenol
• CAS: 70120-14-8
• 化学式: C₁₅H₂₃BrO
• 分子量: 299.251
• InChiKey: HUDFTWYCPXXWIH-UHFFFAOYSA-N

物化性质

• 沸点：
  347.1±22.0 °C(Predicted)
• 密度：
  1.181±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、二氯甲烷、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-溴-5-(1,1-二甲基庚基)苯酚 在 四(三苯基膦)钯 吡啶 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3',5'-dimethyl-4-(2-methyloctan-2-yl)-[1,1'-biphenyl]-2-yl trifluoromethanesulfonate
  参考文献：
  名称：

  Biaryl cannabinoid mimetics—Synthesis and structure–activity relationship

  摘要：

  Synthesis, in vitro biological evaluation, and structure-activity relationships of a biaryl cannabinoid mimetic 2 are reported. Variations in the substitution pattern yielded a number of agonists with low nanomolar affinity. Replacing the phenol group by a methyl morpholino acetate group led to compound 28, a 500-fold selective CB, receptor agonist. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.059
• 作为产物：
  描述：

  2-[3-(苄氧基)苯基]-2-甲基丙腈 在 palladium on activated charcoal sodium hydroxide 、 硫酸 、 氢气 、 溴 、 二异丁基氢化铝 、 二甲基亚砜 作用下， 以 四氯化碳 、 乙醇 为溶剂， 15.0~30.0 ℃ 、344.73 kPa 条件下， 反应 21.25h， 生成 2-溴-5-(1,1-二甲基庚基)苯酚
  参考文献：
  名称：

  大麻素衍生的典型止痛药。

  摘要：

  描述了3- [4-（1,1-二甲基庚基）-2-羟基苯基]环己醇（1）的合成和止痛测试。先前（SAR）的研究使我们得出以下结论：9-nor-9β-羟基六氢大麻酚（HHC）的吡喃环对于该系列大麻素的生物活性表达不是必需的。对模型的分析和分子力学计算的使用表明，较简单的化合物（例如1）将具有HHC的生物活性。由[3-（苄氧基）苯基]乙腈（2）分九步制备化合物1。在五种疼痛模型中进行的生物学测试表明，化合物1和吗啡与镇痛药具有同等效力，并证明HHC的吡喃环对于生物活性不是必需的。通过合成4- [4-（1，

  DOI：

  10.1021/jm00367a013

文献信息

• Phenyl derivatives and methods of use
  申请人：Dolle E. Roland

  公开号：US20060074086A1

  公开（公告）日：2006-04-06

  Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related disorders, and neurodegenerative diseases, for providing cardioprotection against ischemic and reperfusion effects, for inducing apoptosis in malignant cells, and as an appetite stimulant.

  披露了新的苯基化合物、含有这些化合物的药物组合物以及它们的药用方法。在某些实施例中，这些化合物是 cannabinoid 受体的激动剂和/或配体，可能用于治疗和/或预防疼痛、胃肠疾病、泌尿生殖系统疾病、炎症、青光眼、自身免疫疾病、缺血性疾病、免疫相关疾病和神经退行性疾病，用于提供对缺血和再灌注效应的心脏保护，用于诱导恶性细胞的凋亡，以及作为食欲刺激剂。
• 3-[2-Hydroxy-4-(substituted)phenyl]-cycloalkanol analgesic agents
  申请人：Pfizer Inc.

  公开号：US04306097A1

  公开（公告）日：1981-12-15

  Cycloalkanones, cycloalkanols and unsaturated analogs thereof, each of which has at the 3-position a 2-hydroxy-4-substituted phenyl group wherein the 4-position substituent is alkyl which can have an oxygen atom as part of the chain, or aralkyl which can have an oxygen atom as part of the alkyl chain, their use for pharmacological and medicinal purposes, intermediates therefor and processes for their preparation.

  环烷酮、环烷醇及其不饱和类似物，每个在3位上具有一个2-羟基-4-取代苯基团，其中4位取代基是可以在链中具有氧原子的烷基，或者可以在烷基链中具有氧原子的芳基烷基，它们用于药理学和药用目的，以及其中间体和制备过程。
• Modulator
  申请人：Selwood David

  公开号：US20080262011A1

  公开（公告）日：2008-10-23

  The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R 1 and R 2 are each independently H or alkyl; Y is an alkyl group. CONR 3 R 4 , COOR 5 SO 2 NR 16 R 17 , NHSO 2 R 18 or CN; X is an aryl or heteroaryl group, each of which may be optionally substituted with one or more substituents selected from (CH2) m Z where Z is halogen, OH, CN, alkyl, alkoxy, NO 2 , CF 3 , CONR 6 R 7 , CN, NR 8 R 9 , COOR 10 or NHCOR 11 and m is 0 to 3; R 3 to R 11 are each independently H, alkyl or aryl, wherein said alkyl and aryl groups are optionally substituted by one or more substituents selected from halogen, OH, CN, alkyl, alkoxy, NO 2 , CF 3 , CONR 12 R 13 , CN, NH 2 , COOR 14 , NHCOR 15 , and CN; R 12 to R 18 are each independently H or alkyl, more preferably H or Me; n is 1 to 6; wherein the compound is other than 3′,5′-dimethyl-4-(1,1-dimethylheptyl)-1,1′-biphenyl-2-ol. Further aspects of the invention related to the use of such compounds in the preparation of a medicament for the treatment of a muscular disorder, a gastrointestinal disorder, or for controlling spasticity or tremors.

  本发明涉及一种式I化合物或其药学上可接受的盐。式(I)中，R1和R2各自独立地为H或烷基；Y为烷基、CONR3R4、COOR5、SO2NR16R17、NHSO2R18或CN；X为芳基或杂芳基，每个基团可任选地被一个或多个选自(CH2)mZ的取代基取代，其中Z为卤素、OH、CN、烷基、烷氧基、NO2、CF3、CONR6R7、CN、NR8R9、COOR10或NHCOR11，m为0至3；R3至R11各自独立地为H、烷基或芳基，其中所述烷基和芳基基团可任选地被一个或多个选自卤素、OH、CN、烷基、烷氧基、NO2、CF3、CONR12R13、CN、NH2、COOR14、NHCOR15和CN的取代基取代；R12至R18各自独立地为H或烷基，更优选为H或甲基；n为1至6；所述化合物不包括3′,5′-二甲基-4-(1,1-二甲基庚基)-1,1′-联苯-2-醇。本发明的进一步方面涉及此类化合物在制备用于治疗肌肉疾病、胃肠疾病或控制痉挛或震颤的药物中的用途。
• 3-[2-Hydroxy-4-(substituted)-phenyl]azacycloalkanes and derivatives
  申请人：Pfizer Inc.

  公开号：US04147872A1

  公开（公告）日：1979-04-03

  Azacycloalkanes, and derivatives thereof, including unsaturated analogs, each of which has at the 3-position a 2-hydroxy-4-substituted phenyl group wherein the 4-position substituent is alkyl which can have an oxygen atom as part of the chain, or aralkyl which can have an oxygen atom as part of the alkyl chain, their use for pharmacological and medicinal purposes, intermediates therefor and processes for their preparation.

  氮杂环烷及其衍生物，包括不饱和类似物，每个在3位具有一个2-羟基-4-取代苯基团，其中4位取代基是可以在链中具有氧原子的烷基，或者可以在烷基链中具有氧原子的芳基烷基，它们用于药理学和药用目的，以及它们的中间体和制备过程。
• Hydroxyalkyl and oxoalkyl substituted phenols as analgesics and sedatives
  申请人：Pfizer Inc.

  公开号：US04283569A1

  公开（公告）日：1981-08-11

  Compounds useful for pharmacological and medicinal purposes having the formulae ##STR1## wherein R is H, C.sub.1 -C.sub.5 alkanoyl; R.sub.1 is H, benzyl, C.sub.1 -C.sub.5 alkanoyl, P(O)(OH).sub.2, --CO(CH.sub.2).sub.2 COOH or a basic acyl group; each of R.sub.2 and R.sub.4 is H, C.sub.1 -C.sub.6 alkyl, phenyl, pyridyl or (CH.sub.2).sub.y C.sub.6 H.sub.5 ; y is 1-4; R.sub.3 is H or CH.sub.3 ; Z is C.sub.1 -C.sub.13 alkylene or --(alk.sub.1).sub.m --O--(alk.sub.2).sub.n --; each of (alk.sub.1) and (alk.sub.2) is C.sub.1 -C.sub.13 alkylene with the proviso that the summation of carbon atoms in (alk.sub.1) plus (alk.sub.2) is not greater than 13; each of m and n is 0 or 1; and W is H, pyridyl, phenyl, fluorophenyl or chlorophenyl; intermediates therefor and methods for their preparation and use.

  用于药理学和药用目的的化合物，其分子式为##STR1##其中R为H，C.sub.1 -C.sub.5烷酰基；R.sub.1为H，苄基，C.sub.1 -C.sub.5烷酰基，P(O)(OH).sub.2，--CO(CH.sub.2).sub.2 COOH或一种碱性酰基；R.sub.2和R.sub.4中的每一个为H，C.sub.1 -C.sub.6烷基，苯基，吡啶基或(CH.sub.2).sub.y C.sub.6 H.sub.5；y为1-4；R.sub.3为H或CH.sub.3；Z为C.sub.1 -C.sub.13亚烷基或--(alk.sub.1).sub.m--O--(alk.sub.2).sub.n--；(alk.sub.1)和(alk.sub.2)中的每一个为C.sub.1 -C.sub.13亚烷基，但要求(alk.sub.1)加上(alk.sub.2)的碳原子总数不大于13；m和n中的每一个为0或1；W为H，吡啶基，苯基，氟苯基或氯苯基；其中间体以及其制备和使用方法。